Companies competing with ANP in DMD space

@Bigrock2402

There are 2 other players targeting inflammation in the DMD space. Interestingly they are both listed.

Catabasis - CATB.NAS - mkt cap US$126m (1 drug only targeting DMD)

https://www.catabasis.com/CATB-MoveDMD-48-60-Week-Results_13Feb2018_FINAL.pdf

Capicor - CAPR (OTC) - mkt cap US$68m (1 drug only targeting DMD) recent P2 results showed minimal efficacy compared to ANP)

https://www.catabasis.com/CATB-MoveDMD-48-60-Week-Results_13Feb2018_FINAL.pdf

Now... just waiting for the shakedown from Akki.. every post i have put up has had a response from Akki with a very strong negative tone, because Akki knows more than anyone here, is a better investor and more informed than all of us. Don’t let me down Akki.